EHA 2018 European Hematology Association -  June 14-17,  2018
Chronic Myeloid Leukemia - CML -23th Congress of EHA
​Stockholm - Sweden 



Abstract Book


VIDEOS


Timothy Hughes - The importance of achieving early molecular response in CML
June 15, 2018, VJHemOnc – Video Journal of Hematological Oncology

Timothy Hughes - Physicians must perform molecular monitoring regularly for successful outcomes in CML
June 15, 2018, VJHemOnc – Video Journal of Hematological Oncology

Timothy Hughes - Chronic Myeloid Leukaemia (CML) News (part 1 – Treatment free remission)
June 15, 2018, Leukaemia Care

Timothy Hughes - Chronic Myeloid Leukaemia (CML) News (part 2 – New drugs -ABL001)
June 15, 2018, Leukaemia Care

Timothy Hughes - ENESTop: deep molecular response in CML can be translated into treatment-free remission
June 15, 2018, VJHemOnc – Video Journal of Hematological Oncology

Bringing minimal residual disease (MRD) measurement to the clinic
June 14, 2018, VJHemOnc – Video Journal of Hematological Oncology

Leukaemia Care at EHA 2018  
June 14, 2018, Leukaemia Care
                        
Getting the most out of EHA as a CML patient advocate  
June 11, 2018, CML Advocates Network

NEWS

RecurrenceFree Survival May B-e Sustainable After De-Escalation or Stoppage of TKI Therapy in CML
July 6, 2018, Cancer Therapy Advisor

Patients could be spared life-long leukaemia treatment, clinical trial finds
June 27, 2018,  University of Liverpool
              
SOME INTERESTING ABSTRACTS FOR CML

​TREATMENT- FREE REMISSION UP TO 12 YEARS. INTERIM ANALYSIS OF A REGIONAL GERMAN CML - REGISTER. (A CONTRIBUTION OF GERMAN CML - ALLIANCE)

TREATMENT-FREE REMISSION AFTER SECOND-STOP OF IMATINIB THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE

LONG-TERM TREATMENT-FREE REMISSION (TFR) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) FOLLOWING FRONTLINE (1L) NILOTINIB (NIL): RESULTS FROM ENESTFREEDOM

FINAL RESULTS OF THE DESTINY STUDY OF DE-ESCALATION AND STOPPING TREATMENT IN CHRONIC MYELOID LEUKAEMIA
LONG-TERM OUTCOMES OF EARLY CP CML PATIENTS WHO HAVE ACHIEVED CCYR BUT NOT MMR AFTER 24 MONTHS ON FRONTLINE IMATINIB THERAPY

MAINTENANCE THERAPY WITH DASATINIB ADMINISTRATED EVERY OTHER DAY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

PONATINIB 15 MG DAILY, COMBINING EFFICACY AND TOLERABILITY. A RETROSPECTIVE SURVEY IN ITALY

PEG-INTERFERON ΑLPHA 2B CAN IMPROVE MOLECULAR RECURRENCES IN THE TREATMENT-FREE REMISSION; A PILOT STUDY WITH 18-MONTH FOLLOW-UP
​​
EVALUATION OF NK CELLS IN CHRONIC MYELOID LEUKEMIA PATIENTS: CORRELATION WITH RESPONSE TO TREATMENT

CARDIOVASCULAR TOXICITY IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH SECOND-GENERATION TYROSINE KINASE INHIBITORS IN REAL-LIFE PRACTICE. IDENTIFICATION OF RISK FACTORS AND ROLE OF PROPHYLAXIS

LATE MYOCARDIAL TOXICITY IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS ON LONG-TERM TYROSINE KINASE INHIBITOR (TKI) THERAPY

ULTRA-SENSITIVE DETECTION OF TYROSINE KINASE INHIBITOR RESISTANT MUTATIONS IN CHRONIC MYELOID LEUKEMIA PATIENTS USING MISEQ ILLUMINA NEXT GENERATION SEQUENCING PLATFORM
 
THE EVALUATION OF THE TOTAL ANTIOXIDANT CAPACITY IN RELATION TO THE TREATMENT WITH TYROSIN-KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA

RESULTS OF TREATMENT OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND PREGNANCY IN ACCORDANCE WITH THE LEUKEMIC BURDEN AND TERM OF PREGNANCY (THE LET SCHEME)

MATHEMATICAL MODELLING REVEALS THE POTENTIAL FOR CONSIDERABLE DOSE REDUCTIONS IN TYROSINE KINASE INHIBITOR TREATED CHRONIC MYELOID LEUKEMIA
 
QUALITY OF LIFE IN CHRONIC MYELOID LEUKEMIA PATIENTS RECEIVING A TYROSINE KINASE INHIBITOR
 
INTOLERANCES AND HOSPITALIZATIONS AFTER 1, 3 AND 5 YEARS OF TKI THERAPY IN SIMPLICITY, A STUDY OF CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA PATIENTS IN ROUTINE CLINICAL PRACTICE​

​       RETURN to   Congresses, conferences, meetings, ….. on  chronic myeloid leukemia